BR112018013245A2 - método e aparelho para administração óxido nítrico com drogas suplementares - Google Patents

método e aparelho para administração óxido nítrico com drogas suplementares

Info

Publication number
BR112018013245A2
BR112018013245A2 BR112018013245A BR112018013245A BR112018013245A2 BR 112018013245 A2 BR112018013245 A2 BR 112018013245A2 BR 112018013245 A BR112018013245 A BR 112018013245A BR 112018013245 A BR112018013245 A BR 112018013245A BR 112018013245 A2 BR112018013245 A2 BR 112018013245A2
Authority
BR
Brazil
Prior art keywords
administration
nitric oxide
supplementary drugs
supplementary
drugs
Prior art date
Application number
BR112018013245A
Other languages
English (en)
Inventor
H Fine David
Vasquez Gregory
A Dasse Kurt
C Petit Priscilla
Original Assignee
Vero Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vero Biotech LLC filed Critical Vero Biotech LLC
Publication of BR112018013245A2 publication Critical patent/BR112018013245A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

trata-se de um método de proporcionar uma composição terapêutica incluiindo a administração de uma ros reduzindo droga, cálcio bloqueador do canal, anti-fibróticos, anti- inflamatório, ou anti-hipertensivo droga e administração de óxido nítrico inalado, e redução dos sintomas de stress oxidativo e / ou de fibrose num paciente.
BR112018013245A 2015-12-28 2016-12-16 método e aparelho para administração óxido nítrico com drogas suplementares BR112018013245A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562272064P 2015-12-28 2015-12-28
PCT/US2016/067394 WO2017116776A1 (en) 2015-12-28 2016-12-16 Method and apparatus for administering nitric oxide with supplemental drugs

Publications (1)

Publication Number Publication Date
BR112018013245A2 true BR112018013245A2 (pt) 2018-12-04

Family

ID=59088229

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018013245A BR112018013245A2 (pt) 2015-12-28 2016-12-16 método e aparelho para administração óxido nítrico com drogas suplementares

Country Status (7)

Country Link
US (1) US20170182088A1 (pt)
EP (1) EP3397331A4 (pt)
JP (1) JP2019505343A (pt)
AU (1) AU2016382883A1 (pt)
BR (1) BR112018013245A2 (pt)
CA (1) CA3009986A1 (pt)
WO (1) WO2017116776A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113620263A (zh) 2017-02-27 2021-11-09 第三极股份有限公司 生成一氧化氮的系统和方法
MX2020010523A (es) 2017-02-27 2021-02-09 Third Pole Inc Sistemas y metodos para generar oxido nitrico.
WO2018157175A1 (en) 2017-02-27 2018-08-30 Third Pole, Inc. Systems and methods for ambulatory generation of nitric oxide
KR20200083443A (ko) * 2017-08-30 2020-07-08 벨레로폰 펄스 테크놀로지스 엘엘씨 폐질환 관련 폐고혈압의 치료를 위한 흡입 산화질소의 사용
SG11202005974YA (en) * 2017-12-28 2020-07-29 Bellerophon Pulse Tech Llc Use of inhaled nitric oxide and oxygen for the treatment of pulmonary hypertension
WO2020014504A1 (en) * 2018-07-11 2020-01-16 Cyclerion Therapeutics, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS
US11672938B1 (en) 2018-07-18 2023-06-13 Vero Biotech LLC Start-up protocols for nitric oxide delivery device
EP3911393A4 (en) * 2019-01-14 2022-10-19 Bellerophon Therapeutics COMBINATION THERAPIES OF PDE-5 INHIBITORS AND INHALED NITROUS OXIDE
JP6667817B1 (ja) * 2019-03-13 2020-03-18 住友精化株式会社 ガス組成物及びその製造方法、並びにガス製品
JP2022533628A (ja) 2019-05-15 2022-07-25 サード ポール，インコーポレイテッド 一酸化窒素生成用電極
US11479464B2 (en) 2019-05-15 2022-10-25 Third Pole, Inc. Systems and methods for generating nitric oxide
RU197115U1 (ru) * 2019-12-17 2020-04-01 Андрей Алексеевич Сорокин Портативный аппарат ингаляционного наркоза
WO2021142472A1 (en) 2020-01-11 2021-07-15 Third Pole, Inc. Systems and methods for nitric oxide generation with humidity control
WO2021216866A1 (en) * 2020-04-24 2021-10-28 The Trustees Of Columbia University In The City Of New York Methods for treating diseases by targeting oncogenic lipids
US20210395905A1 (en) 2020-06-18 2021-12-23 Third Pole, Inc. Systems and methods for preventing and treating infections with nitric oxide
WO2023049873A1 (en) 2021-09-23 2023-03-30 Third Pole, Inc. Systems and methods for delivering nitric oxide

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US6677433B2 (en) * 1999-01-27 2004-01-13 The Regents Of The University Of California Stabilization of hypoallergenic, hyperdigestible previously reduced proteins
US6601580B1 (en) * 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
US7220421B2 (en) * 2001-06-19 2007-05-22 The Regents Of The University Of California Moraxella bovis cytotoxin, cytotoxin gene, antibodies and vaccines for prevention and treatment of Moraxella bovis infections
US8133903B2 (en) * 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
US8134010B2 (en) * 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
EP1789119B1 (en) * 2004-08-18 2017-10-18 Geno LLC Conversion of nitrogen dioxide (no2) to nitric oxide (no)
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
WO2009155689A1 (en) * 2008-06-24 2009-12-30 Micropharma Limited Nitric oxide device and method for wound healing, treatment of dermatological disorders and microbial infections
US20120093948A1 (en) * 2009-11-20 2012-04-19 Fine David H Nitric Oxide Treatments
JP5581500B2 (ja) * 2010-03-10 2014-09-03 学校法人北里研究所 虚血再灌流障害軽減用治療剤および治療装置
US8586527B2 (en) * 2011-10-20 2013-11-19 Jaipal Singh Cerivastatin to treat pulmonary disorders
US20140127330A1 (en) * 2012-11-05 2014-05-08 Geno Llc Method of mixing gases including nitric oxide
US20150073535A1 (en) * 2013-09-12 2015-03-12 Abbott Cardiovascular Systems Inc. Treatment of coronary artery lesions with a scaffold having vessel scaffold interactions that reduce or prevent angina

Also Published As

Publication number Publication date
CA3009986A1 (en) 2017-07-06
AU2016382883A1 (en) 2018-07-12
US20170182088A1 (en) 2017-06-29
EP3397331A1 (en) 2018-11-07
WO2017116776A1 (en) 2017-07-06
JP2019505343A (ja) 2019-02-28
EP3397331A4 (en) 2019-08-21

Similar Documents

Publication Publication Date Title
BR112018013245A2 (pt) método e aparelho para administração óxido nítrico com drogas suplementares
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
MY188139A (en) Sodium channel modulators for the treatment of pain
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
BR112016017193A2 (pt) Derivados de insulina, seus usos, e composição farmacêutica
BR112017009986A2 (pt) métodos para tratar indivíduos com síndrome de prader-willi ou síndrome de smith-magenis
PH12019500061A1 (en) Oral gastroretentive formulations and uses thereof
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
BR112012000862A8 (pt) composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamento
BR112018072988A2 (pt) irinotecano lipossômico para uso no tratamento de câncer de pulmão de pequenas célula
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
LT3784210T (lt) Vietinė farmacinė kompozicija, skirta išangės įtrūkimų ir hemorojaus gydymui
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2014119985A3 (es) Composición farmacéutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral
BR112017022984A2 (pt) dispositivo para facilitar o posicionamento de um cateter para administrar um medicamento em um paciente que esteja respirando espontaneamente
BR112018009476A2 (pt) regime de dosagem de plasminogênio para cicatrização de ferimentos
BR112018072177A2 (pt) composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
MX2014005152A (es) Composicion farmaceutica para el tratamiento de alopatias relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol.
MX2016006375A (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
EA201790089A1 (ru) Фармацевтические средства для лечения головокружения различной этиологии

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2610 DE 12-01-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.